Sarah Ryan, PhD, University of Manchester, Manchester, UK, discusses the future of research into the NLRP3 inflammasome in frontotemporal dementia and Alzheimer’s disease. Areas of investigation include moving from in vitro to in vivo studies and repurposing NLRP3-targeted drugs, such as mefenamic acid, which are already approved for use in other diseases. This interview took place at the Alzheimer’s Research UK Conference 2022 in Brighton, UK.
